MX2024011776A - Proteínas anti-cd3 y anti-pd-l1 biespecíficas activables y usos de las mismas - Google Patents
Proteínas anti-cd3 y anti-pd-l1 biespecíficas activables y usos de las mismasInfo
- Publication number
- MX2024011776A MX2024011776A MX2024011776A MX2024011776A MX2024011776A MX 2024011776 A MX2024011776 A MX 2024011776A MX 2024011776 A MX2024011776 A MX 2024011776A MX 2024011776 A MX2024011776 A MX 2024011776A MX 2024011776 A MX2024011776 A MX 2024011776A
- Authority
- MX
- Mexico
- Prior art keywords
- proteins
- activatable
- activatable bispecific
- protein molecules
- bispecific anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263325437P | 2022-03-30 | 2022-03-30 | |
| PCT/EP2023/058418 WO2023187130A1 (en) | 2022-03-30 | 2023-03-30 | Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024011776A true MX2024011776A (es) | 2025-01-09 |
Family
ID=86052101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024011776A MX2024011776A (es) | 2022-03-30 | 2024-09-25 | Proteínas anti-cd3 y anti-pd-l1 biespecíficas activables y usos de las mismas |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250109206A1 (https=) |
| EP (1) | EP4499232A1 (https=) |
| JP (1) | JP2025511002A (https=) |
| KR (1) | KR20240163741A (https=) |
| CN (1) | CN119677780A (https=) |
| AU (1) | AU2023246985A1 (https=) |
| CA (1) | CA3246893A1 (https=) |
| IL (1) | IL315768A (https=) |
| MX (1) | MX2024011776A (https=) |
| WO (1) | WO2023187130A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121851177A (zh) * | 2023-12-11 | 2026-04-14 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| CN110590955B (zh) * | 2018-09-17 | 2021-05-18 | 北京盛诺基医药科技股份有限公司 | 一种双特异性抗体 |
| GB201906685D0 (en) * | 2019-05-13 | 2019-06-26 | Ultrahuman Six Ltd | Activatable protein constructs and uses thereof |
-
2023
- 2023-03-30 IL IL315768A patent/IL315768A/en unknown
- 2023-03-30 KR KR1020247035680A patent/KR20240163741A/ko active Pending
- 2023-03-30 AU AU2023246985A patent/AU2023246985A1/en active Pending
- 2023-03-30 EP EP23717433.9A patent/EP4499232A1/en active Pending
- 2023-03-30 CA CA3246893A patent/CA3246893A1/en active Pending
- 2023-03-30 WO PCT/EP2023/058418 patent/WO2023187130A1/en not_active Ceased
- 2023-03-30 JP JP2024557583A patent/JP2025511002A/ja active Pending
- 2023-03-30 CN CN202380038600.4A patent/CN119677780A/zh active Pending
-
2024
- 2024-09-19 US US18/889,571 patent/US20250109206A1/en active Pending
- 2024-09-25 MX MX2024011776A patent/MX2024011776A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023187130A1 (en) | 2023-10-05 |
| EP4499232A1 (en) | 2025-02-05 |
| AU2023246985A1 (en) | 2024-10-03 |
| CA3246893A1 (en) | 2023-10-05 |
| KR20240163741A (ko) | 2024-11-19 |
| US20250109206A1 (en) | 2025-04-03 |
| JP2025511002A (ja) | 2025-04-15 |
| CN119677780A (zh) | 2025-03-21 |
| IL315768A (en) | 2024-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201990781A9 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| NZ790656A (en) | Antibodies and fusion proteins that bind to ccr8 and uses thereof | |
| EA202091977A1 (ru) | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения | |
| ZA201901557B (en) | Bi specific anti¿muc16¿cd3 antibodies and anti¿muc16 drug conjugates | |
| MX2023010499A (es) | Anticuerpos heterodimericos que se unen a cd3 y cldn6. | |
| EA201890368A1 (ru) | Антитела против псма, биспецифичные антигенсвязывающие молекулы, которые связывают псма и cd3, и их применение | |
| MX2021014193A (es) | Moleculas de enlace biespecificas anti-ror1/anti-cd3. | |
| EA201890785A1 (ru) | Оптимизированные биспецифические анти-cd3 антитела и их применение | |
| MX2023014645A (es) | Proteinas acopladoras de celulas nk de union a nkp46 especificas de cd20. | |
| EA201590613A1 (ru) | Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения | |
| PH12022551960A1 (en) | Antibodies binding to b7h4 | |
| MX2024011776A (es) | Proteínas anti-cd3 y anti-pd-l1 biespecíficas activables y usos de las mismas | |
| MX2022010161A (es) | Proteínas biespecíficas anti-her2 diseñadas. | |
| MX2023002002A (es) | Proteinas de union restringidas activadas de forma condicional. | |
| BR112021018632A2 (pt) | Moléculas de ligação ao cd3 | |
| ATE387909T1 (de) | Verfahren und zusammensetzungen zur behandlung von neoplastischen erkrankungen mittels chemotherapie und strahlungssensibilisatoren | |
| WO2022082030A3 (en) | Antigen-binding proteins and related methods of use | |
| MX2023012300A (es) | Anticuerpos humanos contra artemina y metodos de uso de estos. | |
| JOP20250032A1 (ar) | بروتينات ترتبط ب nkg2d، cd16، وceacam5 | |
| WO2025080685A3 (en) | Antibody molecules that bind to nkp30 and uses thereof | |
| MX2021008453A (es) | Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos. | |
| WO2023039611A3 (en) | Tfr antigen binding proteins and uses thereof | |
| MX2025006535A (es) | Anticuerpos biespecificos que se dirigen a pd1 y vegf | |
| EA202190314A1 (ru) | Биспецифические анти-bcma x анти-cd3 антитела и способы их применения | |
| MX2026000166A (es) | Anticuerpos biespecificos pd-l1x4-1bb y metodos de uso de los mismos |